Aligos Therapeutics, Inc. (ALGS)
5.54
+0.20
(+3.75%)
USD |
NASDAQ |
Oct 12, 12:00
Aligos Therapeutics Max Drawdown (5Y) : 99.54% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 99.54% |
| August 31, 2026 | 99.54% |
| July 31, 2026 | 99.54% |
| June 30, 2026 | 99.54% |
| May 31, 2026 | 99.54% |
| April 30, 2026 | 99.54% |
| March 31, 2026 | 99.54% |
| February 28, 2026 | 99.54% |
| January 31, 2026 | 99.54% |
| December 31, 2025 | 99.54% |
| November 30, 2025 | 99.54% |
| October 31, 2025 | 99.54% |
| September 30, 2025 | 99.54% |
| August 31, 2025 | 99.54% |
| July 31, 2025 | 99.54% |
| June 30, 2025 | 99.54% |
| May 31, 2025 | 99.54% |
| April 30, 2025 | 99.54% |
| March 31, 2025 | 99.21% |
| February 28, 2025 | 99.21% |
| January 31, 2025 | 99.21% |
| December 31, 2024 | 99.21% |
| November 30, 2024 | 99.21% |
| October 31, 2024 | 99.21% |
| September 30, 2024 | 99.08% |
| Date | Value |
|---|---|
| August 31, 2024 | 99.00% |
| July 31, 2024 | 99.00% |
| June 30, 2024 | 99.00% |
| May 31, 2024 | 98.40% |
| April 30, 2024 | 98.40% |
| March 31, 2024 | 98.40% |
| February 29, 2024 | 98.40% |
| January 31, 2024 | 98.40% |
| December 31, 2023 | 98.40% |
| November 30, 2023 | 98.31% |
| October 31, 2023 | 98.29% |
| September 30, 2023 | 97.97% |
| August 31, 2023 | 97.54% |
| July 31, 2023 | 97.50% |
| June 30, 2023 | 97.50% |
| May 31, 2023 | 97.50% |
| April 30, 2023 | 97.50% |
| March 31, 2023 | 97.50% |
| February 28, 2023 | 97.44% |
| January 31, 2023 | 97.44% |
| December 31, 2022 | 97.44% |
| November 30, 2022 | 97.44% |
| October 31, 2022 | 97.14% |
| September 30, 2022 | 97.14% |
| August 31, 2022 | 97.02% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Agenus, Inc. | 98.84% |
| Amgen, Inc. | 24.86% |
| Anika Therapeutics, Inc. | 83.15% |
| BioCryst Pharmaceuticals, Inc. | 79.10% |
| Imunon, Inc. | 99.49% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -84.54 |
| Beta (5Y) | 2.364 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 127.6% |
| Historical Sharpe Ratio (5Y) | -0.4772 |
| Historical Sortino (5Y) | -1.068 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 48.12% |